# US 2021/0080460 A1 · Reagents, methods and kits for diagnosing primary immunodeficiencies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0080460 A1
- Document ID: US20210080460A1
- Status: Published application
- Kind: A1
- Application number: 17/031,732
- Filed: 2020-09-24
- Published: 2021-03-18
- Earliest claimed: 2014-10-30
- Assignees: Erasmus University Medical Center Rotterdam
- Applicants: Erasmus University Medical Center Rotterdam
- Inventors: Jacobus Johannes Maria VAN DONGEN; José Alberto ORFAO DE MATOS CORREIA E VALE; Mirjam VAN DER BURG; Martín PÉREZ-ANDRÉS; Menno Cornelis VAN ZELM; Tomás KALINA; Marcela VLKOVÁ; Eduardo LÓPEZ-GRANADOS; Elena BLANCO ÁLVAREZ; Anne-Kathrin KIENZLER
- Web page: https://patentgrep.com/patent/US20210080460A1

## CPC

- G01N 33/56972: {White blood cells}
- G01N 15/1459: {the analysis being performed on a sample stream}
- G01N 33/4915: {using flow cells (flow cytometry G01N15/14)}
- G01N 2015/016: {White blood cells}
- G01N 2015/1006: {for cytology}
- G01N 2015/1402: {Data analysis by thresholding or gating operations performed on the acquired signals or stored data}
- G01N 2015/1477: {Multiparameters}
- G01N 2015/1488: {Methods for deciding}
- G01N 2800/24: Immunology or allergic disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention relates to the field of primary immunodeficiencies (PID), more specifically to means and method for the diagnosis of PID of the lymphoid system. Provided are unique reagent compositions for the flow cytometric immunophenotyping of leukocytes comprising fluorochrome-conjugated antibodies directed against various specific combinations of markers. Also provided are kits comprising the reagent compositions, and methods using the same.

## Claims

### Claim 1

A reagent composition for the flow cytometric immunophenotyping of leukocytes comprising fluorochrome-conjugated antibodies directed against the following combination of markers:
CD27, CD45RA, CD8, IgD, CD16, CD56, CD4, IgM, CD19, CD3, CD45, and either TCRαβ or TCRγδ, wherein the antibody within the pairs CD8/IgD, CD16/CD56, CD4/IgM and CD19/TCRαβ or CD19/TCRγδ is conjugated to the same fluorochrome, and wherein between different pairs the fluorochromes are distinguishable.

### Claim at position 2

2-29. (canceled)

### Claim 30 (depends on 1)

The reagent composition of claim 1 further comprising a fluorochrome-conjugated antibody against the markers CCR7 or CD38.

### Claim 31 (depends on 30)

The reagent composition of claim 30, wherein the reagent composition comprises a fluorochrome-conjugated antibody against the markers CCR7 and CD38.

### Claim 32 (depends on 1)

The reagent composition of claim 1, wherein each reagent composition comprises antibodies conjugated to (1) pacific blue (PacB), brilliant violet 421 (BV421) or Horizon V450; (2) pacific orange (PacO), Horizon V500 (HV500), BV510, Khrome orange (KO) or OC515, (3) Horizon BB515, fluorescein isothiocyanate (FITC) or Alexa488, (4) phycoerythrin (PE), (5) peridinin chlorophyl protein/cyanine 5.5 (PerCP-Cy5.5), PerCP or PE-TexasRed, (6) phycoerythrin/cyanine7 (PE-Cy7), (7) allophycocyanine (APC) or Alexa647, and (8) allophycocyanine/hilite 7 (APC-H7), APC-Cy7, Alexa680, APC-A750, APC-C750 or Alexa700.

### Claim 33 (depends on 30)

The reagent composition of claim 30, wherein each reagent composition comprises antibodies conjugated to (1) brilliant violet 421, (2) brilliant violet 510 (BV510), (3) brilliant violet 650 (BV650), (4) brilliant violet 786 (BV786), (5) fluorescein isothiocyanate (FITC), (6) peridinin chlorophyl protein/cyanine 5.5 (PerCP-Cy5.5), (7) to phycoerythrin (PE), (8) phycoerythrin/cyanine7 (PE-Cy7), (9) allophycocyanine (APC), and (10) allophycocyanine/H7 (APC-H7), APC-C750 or APC-Alexa750.

### Claim 34 (depends on 1)

A kit comprising:
(i) the reagent composition of claim 1; and
(ii) a second reagent composition comprising the following combination of markers: CD62L, HLA-DR, CD8, CD31, CD4, CD3, CD45RO, and either TCRγδ or TCRαβ.

### Claim 35 (depends on 1)

A kit comprising:
(i) the reagent composition of claim 1;
(ii) a second reagent composition comprising fluorochrome-conjugated antibodies against the following combination of markers: CD27, IgM, CD38, CD5, IgD, CD19, CD21, CD24; and
(iii) a third reagent composition comprising fluorochrome-conjugated antibodies against the following combination of markers: CD27, IgM, IgA, IgG, IgD, CD19, CD21, CD38.

### Claim 36 (depends on 35)

The kit of claim 35, wherein the third reagent composition further comprises a fluorochrome-conjugated antibody against IgE, and wherein the antibodies within the pair IgE/IgA are conjugated to the same fluorochrome, and wherein the fluorochrome is distinguishable from the other fluorochromes.

### Claim 37 (depends on 35)

The kit of claim 35, wherein the third reagent composition comprises two distinctly labeled antibodies against IgA, wherein the first antibody against IgA and the antibody against IgE are each conjugated to a first fluorochrome, and wherein the second antibody against IgA and the antibody against IgG are each conjugated to a second fluorochrome; and wherein the first and the second fluorochromes are distinguishable.

### Claim 38 (depends on 1)

A kit comprising:
(i) the reagent composition of claim 1;
(ii) a second reagent composition comprising the following combination of markers: CD27, IgM, IgG3, IgG2, IgG1, IgG2, IgD, CD19, CD21, CD38; wherein the reagent composition comprises two distinctly labeled antibodies against IG2, wherein the first antibody against IgG2 and the antibody against IgG3 are each conjugated to a first fluorochrome, and wherein the second antibody against IgG2 and the antibody against IgG1 are each conjugated to a second fluorochrome; and wherein the first and the second fluorochromes are distinguishable; and
(iii) a third reagent composition comprising the following combination of markers: CD27, IgM, IgA, IgG4, IgA2, IgD, CD19, CD21, CD38; wherein the reagent composition comprises two distinctly labeled antibodies against IgA1, wherein the first antibody against IgA1 and the antibody against IgG4 are each conjugated to a third fluorochrome, and wherein the second antibody against IgA1 and the antibody against IgA2 are each conjugated to a fourth fluorochrome; and wherein the third and the fourth fluorochromes are distinguishable.

### Claim 39 (depends on 30)

A kit comprising:
(i) the reagent composition of claim 30; and
(ii) a second reagent composition comprising the following combination of markers: CD27, HLA-DR, CD45RO, CD3, CD8, CD4, CCR7, CD31, CD62L, and either TCRαβ or TCRγδ.

### Claim 40 (depends on 30)

A kit comprising:
(i) the reagent composition of claim 30;
(ii) a second reagent composition comprising the following combination of markers: CD27, IgM, CD24, CD19, IgE, IgA, CD5, IgG, IgD, CD21, CD38; wherein the reagent composition comprises two distinctly labeled antibodies against IgA, wherein the first antibody against IgA and the antibody against IgE are each conjugated to a first fluorochrome, and wherein the second antibody against IgA and the antibody against IgG are each conjugated to a second fluorochrome; and wherein the first and the second fluorochromes are distinguishable; and
(iii) a third reagent composition comprising the following combination of markers: CD27, IgM, CD24, CD19, IgG3, IgG2, IgA1, IgA2, IgG1, IgD, IgG4, CD38; wherein the reagent composition comprises two distinctly labeled antibodies against IgG2, wherein the first antibody against IgG2 and the antibody against IgG3 are each conjugated to a third fluorochrome, and wherein the second antibody against IgG2 and the antibody against IgG1 are each conjugated to a fourth fluorochrome; and wherein the third and the fourth fluorochromes are distinguishable;
wherein the reagent composition comprises two distinctly labeled antibodies against IgA1, wherein the first antibody against IgA1 and the antibody against IgA2 are each conjugated to a fifth fluorochrome, and wherein the second antibody against IgA1 and the antibody against IgG4 are each conjugated to a sixth fluorochrome; and wherein the fifth and the sixth fluorochromes are distinguishable.
